MedTrace Logo

Sertraline Hydrochloride 100 mg Tablets, Fasting

NCT00836849 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-08-19

No results posted yet for this study

Summary

The objective of this study is to compare the rate and extent of absorption of sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference) administered as 1 x 100 mg tablet under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Zoloft® 100 mg Tablets

1 x 100 mg, single-dose fed

DRUG

Sertraline hydrochloride 100 mg Tablets

1 x 100 mg, single-dose fed

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Benoit Girard, M.D. · Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2002-04-30
Completion
2002-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00836849 on ClinicalTrials.gov